Page last updated: 2024-12-07

16-dehydropregnenolone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

16-dehydropregnenolone is a naturally occurring steroid hormone precursor. It is synthesized in the adrenal glands and is a precursor to both progesterone and DHEA. Research on 16-dehydropregnenolone is ongoing. It has been shown to have neuroprotective effects in animal models of Alzheimer's disease and Parkinson's disease. It also has anti-inflammatory properties and may be useful in treating conditions such as arthritis. 16-dehydropregnenolone is also being studied for its potential role in cognitive function, mood, and energy levels.'

16,17-didehydropregnenolone : A 3beta-hydroxy-Delta(5)-steroid that is pregnenolone with a double bond between positions 16 and 17. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID92871
CHEBI ID27486
SCHEMBL ID177687
MeSH IDM0044618

Synonyms (48)

Synonym
AC-12900
3beta-hydroxypregna-5,16-dien-20-one
(3beta)-3-hydroxypregna-5,16-dien-20-one
CHEBI:27486
5,16-pregnadien-3beta-ol-20-one
delta(16)-pregnenolone
nsc-15467
.delta.16-pregnenolone
pregna-5, 3.beta.-hydroxy-
16-dehydropregnenolone
1162-53-4
pregna-5, 3-hydroxy-, (3.beta.)-
16-dehydropregnolone
nsc15467
pregna-5,16-dien-20-one, 3.beta.-hydroxy-
pregna-5,16-dien-20-one, 3-hydroxy-, (3.beta.)-
16,17-didehydropregnenolone
3 beta-hydroxy-5,16-pregnadien-20-one
STK801867
LMST02030164
1-[(3s,8r,9s,10r,13s,14s)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-17-yl]ethanone
A803580
1-((3s,8r,9s,10r,13s,14s)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl)ethan-1-one
AKOS005622678
nsc 15467
pregna-5,16-dien-20-one, 3-hydroxy-, (3beta)-
unii-7349506p5s
einecs 214-602-8
7349506p5s ,
delta16-pregnenolone
3.beta.-hydroxy-20-oxopregna-5,16-diene
3.beta.-hydroxy-.delta.5,16-pregnadien-20-one
3.beta.-hydroxypregna-5,16-dien-20-one
(-)-pregnadienolone
pregnadienolone
AB01319784-02
BBL029914
SCHEMBL177687
pregna-5,16-dienolone
pregna-5,16-dien-20-one, 3-hydroxy-, (3b)-
W-108584
mfcd00046219
Q27103159
AS-14017
DTXSID401016789
AMY22297
NCGC00325004-01
pregna-5,16-dien-20-one,3-hydroxy-,(3b)-

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"This manuscript addresses key pharmacokinetic issues in support of the development of a potent candidate lipid-lowering drug molecule, 16-dehydropregnenolone (DHP)."( Preclinical pharmacokinetics, dose proportionality, gender difference and protein binding study of 16-dehydropregnenolone, an antihyperlipidemic agent, in rats.
Gupta, RC; Singh, SK; Suryawanshi, S, 2011
)
0.79
" Pharmacokinetic studies of DHP after intravenous and oral administration were carried out to assess any gender effect."( Preclinical pharmacokinetics, dose proportionality, gender difference and protein binding study of 16-dehydropregnenolone, an antihyperlipidemic agent, in rats.
Gupta, RC; Singh, SK; Suryawanshi, S, 2011
)
0.59
" An increase in the oral dose led to a disproportionate change in peak concentration (C(max) ) and AUC, indicating variable absorption."( Preclinical pharmacokinetics, dose proportionality, gender difference and protein binding study of 16-dehydropregnenolone, an antihyperlipidemic agent, in rats.
Gupta, RC; Singh, SK; Suryawanshi, S, 2011
)
0.59
" The assay was successfully applied to both oral (40 mg kg(-1)) and intravenous (10 mg kg(-1)) pharmacokinetic studies in male Sprague-Dawley rats."( Bioanalytical LC-MS/MS method development and validation of novel antidiabetic candidate S007-1261 in rat plasma and its application to pharmacokinetic and oral bioavailability studies.
Gautam, N; Kushwaha, HN; Misra, A; Pratap, R; Singh, B; Singh, SK; Verma, PC, 2014
)
0.4
"The pharmacokinetic study indicated that the 16-DHP-LM group had higher area under the plasma concentration-time curve (AUC), lower apparent volume of distribution (Vz) and smaller systemic clearance (CL) than the 16-DHP solution group."( Pharmacokinetics and tissue distribution study of 16-dehydropregnenolone liposome in female mice after intravenous administration.
Cui, Y; Deng, Z; Qin, Z; Sun, L; Sun, Y; Wang, F; Wang, X, 2016
)
0.69
" Pharmacokinetic studies after oral administration of 16-DHP-HP-β-CD at doses of 37."( Pharmacokinetics of 16-dehydropregnenolone hydroxypropyl-β-cyclodextrin inclusion complex following peroral administration.
Jia, L; Mao, M; Sun, L; Sun, Y; Wang, X; Wei, L; Zhou, H, 2017
)
0.78

Bioavailability

ExcerptReferenceRelevance
" DHP showed low systemic oral bioavailability and exhibited dose-independent pharmacokinetics and gender differences."( Preclinical pharmacokinetics, dose proportionality, gender difference and protein binding study of 16-dehydropregnenolone, an antihyperlipidemic agent, in rats.
Gupta, RC; Singh, SK; Suryawanshi, S, 2011
)
0.59
" The oral bioavailability of S007-1261 was found to be 33."( Bioanalytical LC-MS/MS method development and validation of novel antidiabetic candidate S007-1261 in rat plasma and its application to pharmacokinetic and oral bioavailability studies.
Gautam, N; Kushwaha, HN; Misra, A; Pratap, R; Singh, B; Singh, SK; Verma, PC, 2014
)
0.4
" The relative bioavailability was researched by comparing the area under the plasma concentration-time curve of 16-DHP-HP-β-CD and free 16-DHP after oral administration in rats at the dose of 75 mg/kg."( Pharmacokinetics of 16-dehydropregnenolone hydroxypropyl-β-cyclodextrin inclusion complex following peroral administration.
Jia, L; Mao, M; Sun, L; Sun, Y; Wang, X; Wei, L; Zhou, H, 2017
)
0.78
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
20-oxo steroidAn oxo steroid carrying an oxo group at position 20.
enoneAn alpha,beta-unsaturated ketone of general formula R(1)R(2)C=CR(3)-C(=O)R(4) (R(4) =/= H) in which the C=O function is conjugated to a C=C double bond at the alpha,beta position.
3beta-hydroxy-Delta(5)-steroidAny 3beta-hydroxy-steroid that contains a double bond between positions 5 and 6.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.85)18.7374
1990's5 (19.23)18.2507
2000's6 (23.08)29.6817
2010's14 (53.85)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.55 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index5.23 (4.65)
Search Engine Demand Index24.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]